From left: Doug Hockstad, Tech Launch Arizona senior director of technology transfer; David Allen, vice president of TLA; Kwansun Ahn, Anivive CEO; Dylan Balsz, Anivive co-founder; Codey Arbuckle, Anivive director of engineering; Warren Rickard, Anivive co-founder; and Paul Eynott, TLA senior licensing manager. (Photo: Taylor Hudson/Tech Launch Arizona)
The University of Arizona has exclusively licensed the rights to novel kinase inhibitor, PX-886 to Anivive Lifesciences, which is developing the drug as a best in class treatment for solid tumors in canines. To date, the Center for Veterinary Medicine at the FDA has approved only two drugs to treat cancer in dogs.
PX-886, which has been shown to be effective in the treatment of a variety of solid tumors in canines, was developed by Garth Powis, formerly of the University’s College of Medicine, in collaboration with colleagues at the University of Pittsburgh, Sanford Burnham Prebys Medical Discovery Institute and Cascadian Pharmaceuticals.
The core mission of Anivive Lifesciences of Orange, CA, is to find and leverage novel human therapeutics to meet needs in veterinary medicine.